ArticleNeurochemical research2025
Salidroside Exerts Neuroprotective Effects via Inhibiting Ferroptosis in Mice with Traumatic Brain Injury.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) carries a high incidence of morbidity and mortality worldwide. We aim to explore the neuroprotective effects of Salidroside (Sal) on TBI and the specific mechanisms involved. The controlled cortical impact (CCI) was adopted to induce TBI in mice. Mice were randomly divided into the following groups: Sham group, TBI group, low-dose Sal (Sal-L) group, High-dose Sal (Sal-H) group and the Ferrostatin-1 (Fer) group. Neurological function of mice was assessed by Neurological Severity Score and behavioral tests, with Hematoxylin-eosin and Nissl staining for histological analysis. Terminal deoxynucleotidyl transferase mediated dUTP nick end labeling assay was employed to detect neuronal apoptosis. Evans blue extravasation was observed to assess blood-brain barrier (BBB) permeability. Immunohistochemistry detected the astrocyte and microglial markers. Remyelination was evaluated by immunofluorescent labeling of myelin basic protein and Luxol Fast Blue staining. Reactive oxygen species (ROS), malondialdehyde, and glutathione levels were detected to assess lipid peroxidation. Ferroptosis was accessed by Prussian blue staining and western blot. Sal improved neurological deficits, reduced histopathological damage, inhibited neuronal apoptosis, and maintained neuronal structural stability in TBI mice. Sal downregulated the expression of Glial Fibrillary Acidic Protein (GFAP) and Iba1, indicating the suppression of astrocyte and microglia activation. Additionally, Sal alleviated BBB damage and promoted myelin regeneration. Sal treatment caused a decrease in ROS and malondialdehyde (MDA), while an increase in glutathione. Notably, Sal exhibited inhibitory effects on ferroptosis, as evidenced by reduced iron deposits, decreased iron ion levels, and modulated expression of key proteins involved in the ferroptosis, including upregulation of ferroptosis-inhibitory proteins and downregulation of ferroptosis-promoting proteins. Sal inhibits lipid peroxidation to suppress ferroptosis, thus exerting a neuroprotective effect on TBI mice.
Indexed as
Identifiers
40542883What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.